All of their US revenue is generated from inpatient procedures. Hospitals are paid under a diagnostic-related group (DRG) system for the patient's hospital's stay rather than paying for each individual service. Major hospitals, such as the Clevland Clinic, use BTM because of its clinical efficacy and cost savings. BTM is currently not approved for outpatient procedures, which are paid for based on individual service.
The Centers for Medicare & Medicaid Services (CMS) is currently evaluating their payment system for outpatient procedures.
Proposed LCD - Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers (DL35041) (cms.gov)
The Clinicians Speak, page-1001
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.27 |
Change
-0.140(5.81%) |
Mkt cap ! $1.566B | |||
| Open | High | Low | Value | Volume |
| $2.43 | $2.43 | $2.26 | $4.355M | 1.881M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 15056 | $2.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.28 | 50883 | 9 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| PNV (ASX) Chart |